These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant ☒
Filed by a party other than the Registrant ☐
Check the appropriate box:
| ☐ |
Preliminary Proxy Statement |
| ☐ |
Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) |
| ☒ |
Definitive Proxy Statement |
| ☐ |
Definitive Additional Materials |
| ☐ |
Soliciting Material Pursuant to §240.14a-12 |
ARCELLX, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| ☒ |
No fee required. |
| ☐ |
Fee paid previously with preliminary materials. |
| ☐ |
Fee computed on table in exhibit required by Item 25(b) perExchange ActRules 14a-6(i)(1) and0-11 |
800 Bridge Parkway
Redwood City, CA 94065
(240) 327-0603
April11, 2024
Dear Fellow Stockholders:
We are pleased to invite you to attend the annual meeting of stockholders of Arcellx, Inc., to be held on Friday, May24, 2024 at 9:00 am, ET. The annual meeting will be conducted virtually via live audio webcast. You will be able to attend the annual meeting virtually by visiting www.proxydocs.com/ACLX, where you will be able to listen to the meeting live, submit questions and vote online.
The attached formal meeting notice and proxy statement contain details of the business to be conducted at the annual meeting.
Your vote is important. Whether or not you attend the annual meeting, it is important that your shares be represented and voted at the annual meeting. Therefore, we urge you to vote and submit your proxy promptly via the Internet, telephone or mail.
On behalf of our Board of Directors, we would like to express our appreciation for your continued support of and interest in Arcellx.
|
Sincerely, |
|
|
Rami Elghandour |
|
President, Chief Executive Officer and Chairman |
ARCELLX, INC.
800 Bridge Parkway
Redwood City, CA 94065
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
| Time and Date | 9:00 am, ET, on Friday, May24, 2024 | |
| Place | The annual meeting will be conducted virtually via live audio webcast. You will be able to attend the annual meeting virtually by visiting www.proxydocs.com/ACLX, where you will be able to listen to the meeting live, submit questions and vote online during the meeting. | |
| Items of Business |
To elect three ClassII directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified. To approve, on an advisory basis, the compensation of the named executive officers identified in the 2023 Summary Compensation Table in the Executive Compensation section of the proxy statement (the Say-on-Pay Vote). To approve, on an advisory basis, the frequency of future Say-on-Pay Votes. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December31, 2024. To transact other business that may properly come before the annual meeting or any adjournments or postponements thereof. |
|
| Record Date |
April1, 2024 Only stockholders of record as of April1, 2024 are entitled to notice of and to vote at the annual meeting. |
|
| Availability of Proxy Materials |
The Notice of Internet Availability of Proxy Materials containing instructions on how to access our proxy statement, notice of annual meeting, form of proxy and our annual report, is first being sent or given on or about April 11, 2024 to all stockholders entitled to vote at the annual meeting . The proxy materials and our annual report can be accessed as of April11, 2024 by visiting www.proxydocs.com/ACLX. |
|
| Voting | Your vote is important . Whether or not you plan to attend the annual meeting, we urge you to submit your proxy or voting instructions via the Internet, telephone or mail as soon as possible. | |
| By order of the Board of Directors, | ||
|
||
| Rami Elghandour | ||
| President, Chief Executive Officer and Chairman | ||
| Redwood City, CA | ||
| April11, 2024 | ||
-ii-
| Page | ||||||
| QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND OUR ANNUAL MEETING | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1 | VALIGN="bottom"> | |||
| BOARD OF DIRECTORS AND CORPORATE GOVERNANCE | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7 | VALIGN="bottom"> | |||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">8 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">10 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">10 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">10 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">13 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">13 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">13 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">13 | VALIGN="bottom"> | ||||
|
Stockholder Recommendations and Nominations to our Board of Directors |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">14 | VALIGN="bottom"> | |||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">14 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">15 | VALIGN="bottom"> | ||||
|
Corporate Governance Guidelines and Code of Business Conduct and Ethics |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">15 | VALIGN="bottom"> | |||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">15 | VALIGN="bottom"> | ||||
| PROPOSAL NO. 1: ELECTION OF CLASSII DIRECTORS | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">18 | VALIGN="bottom"> | |||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">18 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">18 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">18 | VALIGN="bottom"> | ||||
| PROPOSAL NO. 2: ADVISORY VOTE FOR EXECUTIVE COMPENSATION | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">19 | VALIGN="bottom"> | |||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">19 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">19 | VALIGN="bottom"> | ||||
| PROPOSAL NO.3: ADVISORY VOTE ON THE FREQUENCY OF FUTURE STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">20 | VALIGN="bottom"> | |||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">20 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">20 | VALIGN="bottom"> | ||||
| PROPOSAL NO.4: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">21 | VALIGN="bottom"> | |||
|
Fees Paid to the Independent Registered Public Accounting Firm |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">21 | VALIGN="bottom"> | |||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">21 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">21 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">22 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">22 | VALIGN="bottom"> | ||||
| REPORT OF THE AUDIT COMMITTEE | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">23 | VALIGN="bottom"> | |||
| EXECUTIVE OFFICERS | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">24 | VALIGN="bottom"> | |||
| EXECUTIVE COMPENSATION | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">25 | VALIGN="bottom"> | |||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">25 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">25 | VALIGN="bottom"> | ||||
-iii-
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">29 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">30 | VALIGN="bottom"> | ||||
| SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">35 | VALIGN="bottom"> | |||
| RELATED PERSON TRANSACTIONS | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">37 | VALIGN="bottom"> | |||
| OTHER MATTERS | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">39 | VALIGN="bottom"> | |||
|
Stockholder Proposals or Director Nominations for 2025 Annual Meeting |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">39 | VALIGN="bottom"> | |||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">39 | VALIGN="bottom"> | ||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">39 | VALIGN="bottom"> | ||||
-iv-
ARCELLX, INC.
PROXY STATEMENT
FOR 2024 ANNUAL MEETING OF STOCKHOLDERS
To be held at 9:00 am, ET, on Friday, May24, 2024
The information provided in the question and answer format below is for your convenience only and is merely a summary of the information contained in this proxy statement. You should read this entire proxy statement carefully.
QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND OUR ANNUAL MEETING
Why am I receiving these materials?
This proxy statement and the form of proxy are furnished in connection with the solicitation of proxies by our board of directors for use at the 2024 annual meeting of stockholders of Arcellx, Inc., a Delaware corporation, and any postponements, adjournments or continuations thereof. The annual meeting will be held on Friday, May24, 2024 at 9:00 am, ET. The annual meeting will be conducted virtually via live audio webcast. You will be able to attend the annual meeting virtually by visiting www.proxydocs.com/ACLX, where you will be able to listen to the meeting live, submit questions and vote online during the meeting. Stockholders can go to www.proxydocs.com/ACLX to register to attend the virtual meeting. Stockholders who register to attend will receive an email containing a link to the virtual meeting one hour prior to the meeting start time.
The Notice of Internet Availability of Proxy Materials, or Notice of Internet Availability, containing instructions on how to access this proxy statement, the accompanying notice of annual meeting and form of proxy, and our annual report, is first being sent or given on or about April11, 2024 to all stockholders of record as of April1, 2024. The proxy materials and our annual report can be accessed as of April11, 2024 by visiting www.proxydocs.com/ACLX. If you receive a Notice of Internet Availability, then you will not receive a printed copy of the proxy materials or our annual report in the mail unless you specifically request these materials. Instructions for requesting a printed copy of the proxy materials and our annual report are set forth in the Notice of Internet Availability.
What proposals will be voted on at the annual meeting?
The following proposals will be voted on at the annual meeting:
| |
the election of three ClassII directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified; |
| |
to approve, on an advisory basis, the Say-on-Pay Vote. |
| |
to approve, on an advisory basis, the frequency of future Say-on-Pay Votes. |
| |
the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December31, 2024. |
As of the date of this proxy statement, our management and board of directors were not aware of any other matters to be presented at the annual meeting.
How does the board of directors recommend that I vote on these proposals?
Our board of directors recommends that you vote your shares:
| |
FOR the election of each ClassII director nominee named in this proxy statement; |
| |
FOR the approval, on an advisory basis, of the Say-on-Pay Vote; |
| |
to hold future Say-on-Pay Votes every ONE YEAR; and |
| |
FOR the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December31, 2024. |
Who is entitled to vote at the annual meeting?
Holders of our common stock as of the close of business on April1, 2024, the record date for the annual meeting, may vote at the annual meeting. As of the record date, there were 53,290,315 shares of our common stock outstanding. Each share of common stock is entitled to one vote on each matter properly brought before the annual meeting. Stockholders are not permitted to cumulate votes with respect to the election of directors.
Stockholders of Record . If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A., then you are considered the stockholder of record with respect to those shares, and the Notice of Internet Availability was sent directly to you by us. As a stockholder of record, you have the right to grant your voting proxy directly to the individuals listed on the proxy card or to vote on your own behalf at the annual meeting. Throughout this proxy statement, we refer to these holders as stockholders of record.
Street Name Stockholders . If your shares are held in a brokerage account or by a broker, bank or other nominee, then you are considered the beneficial owner of shares held in street name, and the Notice of Internet Availability was forwarded to you by your broker, bank or other nominee, which is considered the stockholder of record with respect to those shares. As a beneficial owner, you have the right to direct your broker, bank or other nominee on how to vote the shares held in your account by following the instructions that your broker, bank or other nominee sent to you. Throughout this proxy statement, we refer to these holders as street name stockholders.
Is there a list of registered stockholders entitled to vote at the annual meeting?
A list of registered stockholders entitled to vote at the annual meeting will be made available for examination by any stockholder for any purpose germane to the meeting for a period of at least tendays prior to the meeting between the hours of 9:00 a.m. and 4:30 p.m., local time, at our principal executive offices located at 800 Bridge Parkway, Redwood City, CA 94065 by contacting our corporate secretary.
How many votes are needed for approval of each proposal?
| |
Proposal No. 1 : Each director is elected by a plurality of the voting power of the shares present in person (including virtually) or represented by proxy at the annual meeting and entitled to vote on the election of directors. A plurality means that the nominees with the largest number of FOR votes are elected as directors. You may (1)vote FOR the election of each of the director nominees named herein or (2)WITHHOLD authority to vote for each such director nominee. Because the outcome of this proposal will be determined by a plurality vote, any shares not voted FOR a particular nominee, whether as a result of choosing to WITHHOLD authority to vote or a broker non-vote, will have no effect on the outcome of the election. |
| |
Proposal No. 2 : The approval, on an advisory basis, of the Say-on-Pay Vote requires the affirmative vote of a majority of the voting power of the shares present in person (including virtually) or represented by proxy at the annual meeting and entitled to vote thereon. You may vote FOR or AGAINST this proposal, or you may indicate that you wish to ABSTAIN from voting on this proposal. Abstentions will be counted for purposes of determining the presence or absence of a quorum and will also count as votes against this proposal, i.e., will have the same effect as a vote AGAINST this proposal. Broker non-votes will also be counted for purposes of determining the presence or absence of a quorum but will have no effect on the outcome of this proposal. Because this proposal is an advisory vote, the result will not be binding on our board of directors or our company. Our board of directors and our compensation committee will consider the outcome of the vote when determining named executive officer compensation. |
-2-
| |
Proposal No. 3 : For the approval, on an advisory basis, of the frequency of future Say-on-Pay Votes, the choice of frequency that receives the most votes will be considered the preferred frequency of our stockholders. You may vote for a frequency of every ONE YEAR, TWO YEARS or THREE YEARS, or you may indicate that you wish to ABSTAIN from voting on this proposal. Abstentions will be counted for purposes of determining the presence or absence of a quorum but will have no effect on the outcome of this proposal. Broker non-votes will also be counted for purposes of determining the presence or absence of a quorum but will have no effect on the outcome of this proposal. Because this proposal is an advisory vote, the result will not be binding on our board of directors or our company. Our board of directors and our compensation committee will consider the outcome of the vote when determining how often we should submit to stockholders an advisory vote on the compensation of our named executive officers. |
| |
Proposal No. 4 : The ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December31, 2024 requires the affirmative vote of a majority of the voting power of the shares present in person (including virtually) or represented by proxy at the annual meeting and entitled to vote thereon. You may vote FOR or AGAINST this proposal, or you may indicate that you wish to ABSTAIN from voting on this proposal. Abstentions will be counted for purposes of determining the presence or absence of a quorum and will also count as votes against this proposal, i.e., will have the same effect as a vote AGAINST this proposal. Because this is a routine proposal, we do not expect any broker non-votes on this proposal. |
What is the quorum requirement for the annual meeting?
A quorum is the minimum number of shares required to be present or represented at the annual meeting for the meeting to be properly held under our amended and restated bylaws and Delaware law. The presence, in person (including virtually) or by proxy, of a majority of the voting power of our capital stock issued and outstanding and entitled to vote will constitute a quorum to transact business at the annual meeting. Abstentions, choosing to withhold authority to vote and broker non-votes are counted as present and entitled to vote for purposes of determining a quorum. If there is no quorum, the chairperson of the meeting may adjourn the meeting to another time or place.
How do I vote and what are the voting deadlines?
Stockholder of Record . If you are a stockholder of record, you may vote in one of the following ways:
| |
by Internet at www.proxypush.com/ACLX , available by clicking on Vote Now at www.proxydocs.com/ACLX, 24 hours a day, 7 days a week, until 11:59 pm, Eastern time, on May23, 2024 (have your Notice of Internet Availability or proxy card in hand when you visit the website); |
| |
by toll-free telephone at (866 ) 460-4988, 24 hours a day, 7 days a week, until 9:00 am, Eastern time, on May24, 2024 (have your Notice of Internet Availability or proxy card in hand when you call); |
| |
by completing, signing and mailing your proxy card (if you received printed proxy materials), which must be received prior to the annual meeting; or |
| |
by attending the annual meeting virtually by visiting www.proxydocs.com/ACLX, where you may vote during the meeting (have your Notice of Internet Availability or proxy card in hand when you visit the website). |
Street Name Stockholders . If you are a street name stockholder, then you will receive voting instructions from your broker, bank or other nominee. The availability of Internet and telephone voting options will depend on the voting process of your broker, bank or other nominee. We therefore recommend that you follow the voting instructions in the materials you receive. If your voting instruction form or Notice of Internet Availability of proxy materials indicates that you may vote your shares through the proxyvote.com website, then you may vote those shares at the annual meeting with the control number indicated on that voting instruction form or Notice of Internet Availability of proxy materials. Otherwise, you may not vote your shares at the annual meeting unless you obtain a legal proxy from your broker, bank or other nominee.
-3-
What if I do not specify how my shares are to be voted or fail to provide timely directions to my broker, bank or other nominee?
Stockholder of Record . If you are a stockholder of record and you submit a proxy, but you do not provide voting instructions, your shares will be voted:
| |
FOR the election of each ClassII director nominee named in this proxy statement; |
| |
FOR the approval, on an advisory basis, of the Say-on-Pay Vote; |
| |
to hold future Say-on-Pay Votes every ONE YEAR; and |
| |
FOR the ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December31, 2024. |
In addition, if any other matters are properly brought before the annual meeting, the persons named as proxies will be authorized to vote or otherwise act on those matters in accordance with their judgment.
Street Name Stockholders . Brokers, banks and other nominees holding shares of common stock in street name for customers are generally required to vote such shares in the manner directed by their customers. In the absence of timely directions, your broker, bank or other nominee will have discretion to vote your shares on our sole routine matter: the proposal to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December31, 2024. Your broker, bank or other nominee will not have discretion to vote on any other proposals, which are considered non-routine matters, absent direction from you. In the event that your broker, bank or other nominee votes your shares on our sole routine matter, but is not able to vote your shares on the non-routine matters, then those shares will be treated as broker non-votes with respect to the non-routine proposals. Accordingly, if you own shares through a nominee, such as a broker or bank, please be sure to instruct your nominee how to vote to ensure that your shares are counted on each of the proposals.
Can I change my vote or revoke my proxy?
Stockholder of Record . If you are a stockholder of record, you can change your vote or revoke your proxy before the annual meeting by:
| |
entering a new vote by Internet or telephone (subject to the applicable deadlines for each method as set forth above); |
| |
completing and returning a later-dated proxy card, which must be received prior to the annual meeting; |
| |
delivering a written notice of revocation to our corporate secretary at Arcellx, Inc., 800 Bridge Parkway, Redwood City, CA 94065, Attention: Corporate Secretary, which must be received prior to the annual meeting; or |
| |
attending and voting at the annual meeting (although attendance at the annual meeting will not, by itself, revoke a proxy). |
Street Name Stockholders . If you are a street name stockholder, then your broker, bank or other nominee can provide you with instructions on how to change or revoke your proxy.
What do I need to do to attend the annual meeting?
We will be hosting the annual meeting via live audio webcast only.
Stockholder of Record . If you were a stockholder of record as of the record date, then you may attend the annual meeting virtually, and will be able to submit your questions during the meeting and vote your shares electronically during the meeting by visiting www.proxydocs.com/ACLX. Stockholders can go to www.proxydocs.com/ACLX to register to attend the virtual meeting. Stockholders who register to attend, will receive an email containing a link to the virtual meeting one hour prior to
-4-
the meeting start time. To attend and participate in the annual meeting, you will need the control number included on your Notice of Internet Availability or proxy card. The annual meeting live audio webcast will begin promptly at 9:00 am, ET. We encourage you to access the meeting prior to the start time. Online check-in will begin at 8:00 am, ET, and you should allow ample time for the check-in procedures.
Street Name Stockholders . If you were a street name stockholder as of the record date and your voting instruction form or Notice of Internet Availability of proxy materials indicates that you may vote your shares through the proxydocs.com website, then you may access and participate in the annual meeting with the control number indicated on that voting instruction form or Notice of Internet Availability of proxy materials. Otherwise, street name stockholders should contact their bank, broker or other nominee and obtain a legal proxy in order to be able to attend and participate in the annual meeting.
How can I get help if I have trouble checking in or listening to the annual meeting online?
If you encounter difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual meeting log-in page.
What is the effect of giving a proxy?
Proxies are solicited by and on behalf of our board of directors. Rami Elghandour, our President, Chief Executive Officer and Chairman, Michelle Gilson, our Chief Financial Officer, and Maryam Abdul-Kareem, our Chief Legal Officer, have been designated as proxy holders for the annual meeting by our board of directors. When proxies are properly dated, executed and returned, the shares represented by such proxies will be voted at the annual meeting in accordance with the instructions of the stockholder. If the proxy is dated and signed, but no specific instructions are given, however, the shares will be voted in accordance with the recommendations of our board of directors on the proposals as described above. If any other matters are properly brought before the annual meeting, then the proxy holders will use their own judgment to determine how to vote your shares. If the annual meeting is postponed or adjourned, then the proxy holders can vote your shares on the new meeting date, unless you have properly revoked your proxy, as described above.
Who will count the votes?
A representative of Mediant Communications LLC will tabulate the votes and act as inspector of election.
How can I contact Arcellxs transfer agent?
You may contact our transfer agent, Computershare Trust Company, N.A., by telephone at 1-800-736-3001 (US) or 1-781-575-3100 (non-US), or by writing Computershare Trust Company, N.A., at P.O. Box 43006, Providence, RI 02940-3606.You may also access instructions with respect to certain stockholder matters (e.g., change of address) via the internet at www.computershare.com .
How are proxies solicited for the annual meeting and who is paying for such solicitation?
Our board of directors is soliciting proxies for use at the annual meeting by means of the proxy materials. We will bear the entire cost of proxy solicitation, including the preparation, assembly, printing, mailing and distribution of the proxy materials. Copies of solicitation materials will also be made available upon request to brokers, banks and other nominees to forward to the beneficial owners of the shares held of record by such brokers, banks or other nominees. The original solicitation of proxies may be supplemented by solicitation by telephone, electronic communications or other means by our directors, officers or employees. No additional compensation will be paid to these individuals for any such services, although we may reimburse such individuals for their reasonable out-of-pocket expenses in connection with such solicitation.
Where can I find the voting results of the annual meeting?
We will disclose voting results on a Current Report on Form8-K that we will file with the U.S. Securities and Exchange Commission, or SEC, within four business days after the meeting. If final voting results are not available to us in time to file a Form8-K, we will file a Form8-K to publish preliminary results and will provide the final results in an amendment to the Form8-K as soon as they become available.
-5-
Why did I receive a Notice of Internet Availability instead of a full set of proxy materials?
In accordance with the rules of the SEC we have elected to furnish our proxy materials, including this proxy statement and our annual report, primarily via the Internet. As a result, we are mailing to our stockholders a Notice of Internet Availability instead of a paper copy of the proxy materials. The Notice of Internet Availability contains instructions on how to access our proxy materials on the Internet, how to vote on the proposals, how to request printed copies of the proxy materials and our annual report, and how to request to receive all future proxy materials in printed form by mail or electronically by e-mail. We encourage stockholders to take advantage of the availability of the proxy materials on the Internet to help reduce our costs and the environmental impact of our annual meetings.
What does it mean if I receive more than one Notice of Internet Availability or more than one set of printed proxy materials?
If you receive more than one Notice of Internet Availability or more than one set of printed proxy materials, then your shares may be registered in more than one name and/or are registered in different accounts. Please follow the voting instructions on each Notice of Internet Availability or each set of printed proxy materials, as applicable, to ensure that all of your shares are voted.
I share an address with another stockholder, and we received only one copy of the Notice of Internet Availability or proxy statement and annual report. How may I obtain an additional copy of the Notice of Internet Availability or proxy statement and annual report?
We have adopted a procedure approved by the SEC called householding, under which we can deliver a single copy of the Notice of Internet Availability and, if applicable, the proxy statement and annual report, to multiple stockholders who share the same address unless we receive contrary instructions from one or more stockholders. This procedure reduces our printing and mailing costs. Stockholders who participate in householding will continue to be able to access and receive separate proxy cards. Upon written or oral request, we will deliver promptly a separate copy of the Notice of Internet Availability and, if applicable, the proxy statement and annual report, to any stockholder at a shared address to which we delivered a single copy of these documents. To receive a separate copy, or, if you are receiving multiple copies, to request that we only send a single copy of next years Notice of Internet Availability or proxy statement and annual report, as applicable, you may contact us as follows:
Arcellx, Inc.
Attention: Investor Relations
800 Bridge Parkway
Redwood City, CA 94065
Tel: (240) 327-0603
Street name stockholders may contact their broker, bank or other nominee to request information about householding.
-6-
BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
Our board of directors currently consists of seven directors, all of whom except Rami Elghandour, our President and Chief Executive Officer are independent under the listing standards of The Nasdaq Stock Market LLC, or Nasdaq. Our board of directors is divided into three classes with staggered three-year terms. Thus, at each annual meeting of stockholders, a class of directors will be elected for a three-year term to succeed the class whose term is then expiring.
The following table sets forth the names, ages as of April1, 2024, and certain other information for each of our directors and director nominees:
|
Name |
Class |
Age |
Position(s) |
Director
Since |
Current
Term Expires |
Expirationof
Term for Which Nominated
Nominees for Director
|
|
|
|
|
|
|
|
|
|
|
|
|
Jill Carroll (2)(3)
|
|
II
|
|
48
|
|
Director
|
|
2017
|
|
2024
|
|
2027
|
Kavita Patel (2)
|
|
II
|
|
50
|
|
Director
|
|
2021
|
|
2024
|
|
2027
|
Olivia Ware (3)
|
|
II
|
|
67
|
|
Director
|
|
2022
|
|
2024
|
|
2027
|
|
|
|
|
|
|
|
Continuing Directors
|
|
|
|
|
|
|
|
|
|
|
|
|
Rami Elghandour
|
|
III
|
|
45
|
|
Chairman
|
|
2021
|
|
2025
|
|
ALIGN="center">
|
Ali Behbahani (1)(3)
|
|
I
|
|
47
|
|
Director
|
|
2015
|
|
2026
|
|
ALIGN="center">
|
David Lubner (1)(2)
|
|
III
|
|
59
|
|
Director
|
|
2020
|
|
2025
|
|
ALIGN="center">
|
Derek Yoon (1)
|
|
I
|
|
49
|
|
Director
|
|
2020
|
|
2026
|
|
ALIGN="center">
|
|
|
|
|
|
|
|
|
|
|
|
|
ALIGN="center">
|
Jill Carroll . Jill Carroll, M.S. has served as a member of our board of directors since September 2017. Ms.Carroll has served as partner of SR One Capital Management, LP (S.R. One), an entity affiliated with SR One Capital Fund I Aggregator, LP since September 2020. Prior to S.R. One, Ms.Carroll was principal at S.R. One, Limited, initially joining as a Senior Associate in September 2011. From August 2010 to August 2011, Ms.Carroll served as a VP, Corporate Development at Limerick Biopharma. Between May 2004 and August 2010, Ms.Carroll was served as the Senior Director, Strategic Planning Corporate Development at Dynavax Technologies (Nasdaq:DVAX), where she was involved in multiple pharma-partnering deals, as well as substantial private and public financings. Ms.Carroll also served as a director at Clearview Projects from Sept 2001 to May 2004 and as a consultant specializing in health care at Mercer Management Consulting from March 1999 to July 2001. Ms.Carroll is a member of the board of directors of HotSpot Therapeutics, Ancora Biotech and Odyssey Therapeutics. Ms.Carroll received her B.S. in Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University. We believe that Ms.Carroll is qualified to serve our board of directors because of her substantial experience as an investor and her prior management experience as a consultant and as an executive in the biotech industry. Kavita Patel . Kavita Patel, M.D. has served as a member of our board of directors since December 2021. Dr.Patel has been employed as a primary care physician at Marys Center in Washington, DC since January 2020. From January 2011 to January 2022, Dr.Patel has served as a Nonresident Fellow at the Brookings Institution. Dr.Patel has also served as a venture partner at New Enterprise Associates since 2017. Dr.Patel previously served in leadership roles at Johns Hopkins from 2011 to 2018. From 2009 to 2010, she served as Director of Policy for the Office on Intergovernmental Affairs and Public Engagement at The White House. From 2007 to 2009, she served as policy analyst and trusted aide and was part of the senior staff of the Health, Education, Labor and Pensions (HELP) Committee under Senator Edward Kennedys leadership. Dr.Patel currently serves as a member of the board of directors of several non-profit organizations, including SSM Healthcare, a non-profit integrated delivery system. She has also served as a member of the Health and Human Services (HHS) Physician Focused Payment Model Technical Advisory Committee from 2016 to 2021. Dr.Patels prior research in -7- |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
selecting, retaining, compensating, evaluating, overseeing and, where appropriate, terminating our independent registered public accounting firm; |
| |
reviewing and approving the scope and plans for the audits and the audit fees and approving all non-audit and tax services to be performed by the independent auditor; |
-10-
| |
evaluating the independence and qualifications of our independent registered public accounting firm; |
| |
reviewing our financial statements, and discussing with management and our independent registered public accounting firm the results of the annual audit and the quarterly reviews; |
| |
reviewing and discussing with management and our independent registered public accounting firm the quality and adequacy of our internal controls and our disclosure controls and procedures; |
| |
discussing with management our procedures regarding the presentation of our financial information, and reviewing earnings press releases and guidance; |
| |
overseeing the design, implementation and performance of our internal audit function, if any; |
| |
setting hiring policies with regard to the hiring of employees and former employees of our independent auditor and overseeing compliance with such policies; |
| |
reviewing, approving and monitoring related party transactions; |
| |
reviewing and monitoring compliance with our code of business conduct and ethics, and reviewing conflicts of interest of our board members and officers other than related party transactions reviewed by our corporate governance and nominating committee; |
| |
adopting and overseeing procedures to address complaints regarding accounting, internal accounting controls and auditing matters, including confidential, anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters; |
| |
reviewing and discussing with management and our independent auditor the adequacy and effectiveness of our legal, regulatory and ethical compliance programs; and |
| |
reviewing and discussing with management and our independent auditor our guidelines and policies to identify, monitor and address enterprise risks. |
Our audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq. A copy of the charter of our audit committee is available on our website at www.arcellx.com. During 2023, our audit committee held four meetings.
Compensation Committee
The current members of our compensation committee are Ms.Carroll, Dr.Patel and Mr.Lubner. Ms.Carroll is the chairperson of our compensation committee. Our board of directors has determined that each member of our compensation committee meets the requirements for independence for compensation committee members under the rules and regulations of the SEC and the listing standards of Nasdaq. Each member of the compensation committee is also a non-employee director, as defined pursuant to Rule16b-3 promulgated under the Exchange Act. Our compensation committee is responsible for, among other things:
| |
reviewing, approving or making recommendations to our board of directors regarding the compensation for our executive officers, including our chief executive officer; |
| |
reviewing, approving and administering our employee benefit and equity incentive plans; |
| |
establishing and reviewing the compensation plans and programs of our employees, and ensuring that they are consistent with our general compensation strategy; |
-11-
| |
approving or making recommendations to our board of directors regarding the creation or revision of any clawback policy; and |
| |
making recommendations to our board of directors regarding non-employee director compensation. |
Our compensation committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of Nasdaq. A copy of the charter of our compensation committee is available on our website at www.arcellx.com. During 2023, our compensation committee held two meetings.
Corporate Governance and Nominating Committee
The current members of our corporate governance and nominating committee are Mr.Behbahani, Ms.Carroll and Ms.Ware. Mr.Behbahani is the chairperson of our corporate governance and nominating committee. Our board of directors has determined that each member of our corporate governance and nominating committee meets the requirements for independence for corporate governance and nominating committee members under the listing standards of Nasdaq. Our corporate governance and nominating committee is responsible for, among other things:
| |
reviewing and assessing and making recommendations to our board of directors regarding desired qualifications, expertise and characteristics sought of board members; |
| |
identifying, evaluating, selecting or making recommendations to our board of directors regarding nominees for election to our board of directors; |
| |
developing policies and procedures for considering stockholder nominees for election to our board of directors; |
| |
reviewing our succession planning process for our chief executive officer and any other members of our executive management team; |
| |
reviewing and making recommendations to our board of directors regarding the composition, organization and governance our board of directors and its committees; |
| |
reviewing and making recommendations to our board of directors regarding our corporate governance guidelines and corporate governance framework; |
| |
overseeing director orientation for new directors and continuing education for our directors; |
| |
overseeing the evaluation of the performance of our board of directors and its committees; |
| |
reviewing and monitoring compliance with our code of business conduct and ethics, and reviewing conflicts of interest of our board members and officers other than related party transactions reviewed by our audit committee; |
| |
reviewing, approving and monitoring related party transactions; |
| |
administering policies and procedures for communications with the non-management members of our board of directors; and |
| |
monitoring compliance with any stock ownership guidelines. |
Our corporate governance and nominating committee operates under a written charter that satisfies the applicable listing standards of Nasdaq. A copy of the charter of our corporate governance and nominating committee is available on our website at www.arcellx.com. During 2023, our corporate governance and nominating committee held one meeting.
-12-
Attendance at Board and Stockholder Meetings
During our fiscal year ended December31, 2023, our board of directors held four meetings (including regularly scheduled and special meetings), and each director attended at least 75% of the aggregate of (1)the total number of meetings of the board of directors held during the period for which he or she has been a director and (2)the total number of meetings held by all committees on which he or she served during the periods that he or she served.
Although we do not have a formal policy regarding attendance by members of our board of directors at the annual meetings of stockholders, we encourage, but do not require, directors to attend. All of our directors attended our 2023 annual meeting of stockholders.
Executive Sessions of Non-Employee Directors
To encourage and enhance communication among non-employee directors, and as required under applicable Nasdaq rules, our corporate governance guidelines provide that the non-employee directors will meet in executive sessions without management present on a periodic basis. In addition, if any of our non-employee directors are not independent directors, then our independent directors will also meet in executive session on a period basis.
Compensation Committee Interlocks and Insider Participation
During 2023, the members of our compensation committee were Ms.Carroll, Dr.Patel and Mr.Lubner. None of the members of our compensation committee is or has been an officer or employee of our company. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions) of any entity that has one or more executive officers serving on our board of directors or compensation committee. See Related Person Transactions elsewhere in this proxy statement for more information regarding certain transactions involving members of our compensation committee and/or affiliates of such members requiring disclosure under Item 404 of Regulation S-K.
Considerations in Evaluating Director Nominees
Our corporate governance and nominating committee uses a variety of methods for identifying and evaluating potential director nominees. In its evaluation of director candidates, including the current directors eligible for re-election, our corporate governance and nominating committee will consider the current size and composition of our board of directors and the needs of our board of directors and the respective committees of our board of directors and other director qualifications. While our board has not established minimum qualifications for board members, some of the factors that our corporate governance and nominating committee considers in assessing director nominee qualifications include, without limitation, issues of character, professional ethics and integrity, judgment, business experience and diversity, and with respect to diversity, such factors as race, ethnicity, gender, differences in professional background, age and geography, as well as other individual qualities and attributes that contribute to the total mix of viewpoints and experience represented on our board. Although our board of directors does not maintain a specific policy with respect to board diversity, our board of directors believes that the board should be a diverse body, and the corporate governance and nominating committee considers a broad range of perspectives, backgrounds and experiences.
If our corporate governance and nominating committee determines that an additional or replacement director is required, then the committee may take such measures as it considers appropriate in connection with its evaluation of a director candidate, including candidate interviews, inquiry of the person or persons making the recommendation or nomination, engagement of an outside search firm to gather additional information, or reliance on the knowledge of the members of the committee, board or management.
After completing its review and evaluation of director candidates, our corporate governance and nominating committee recommends to our full board of directors the director nominees for selection. Our corporate governance and nominating committee has discretion to decide which individuals to recommend for nomination as directors and our board of directors has the final authority in determining the selection of director candidates for nomination to our board.
-13-
Board Diversity Matrix
The table below provides certain highlights of the composition of our Board members and nominees as of April11, 2024. Each of the categories listed in the table below has the meaning as it is used in Nasdaq Rule 5605(f).
|
Total Number of Directors: |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> 7 | VALIGN="bottom"> | |||||||||
|
Part I: Gender Identity |
Female | Male | ||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">4 | VALIGN="bottom"> | |||||||
|
Part II: Demographic Background* |
||||||||||||
|
African American or Black |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||
|
Asian |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2 | VALIGN="bottom"> | ||||||
|
White |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1 | VALIGN="bottom"> | ||||||
|
Did Not Disclose Demographic Background |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1 | VALIGN="bottom"> | |||||||||
| * |
Directors who identify as Middle Eastern or North African: 2 |
Stockholder Recommendations and Nominations to our Board of Directors
Our corporate governance and nominating committee will consider recommendations and nominations for candidates to our board of directors from stockholders in the same manner as candidates recommended to the committee from other sources, so long as such recommendations and nominations comply with our amended and restated certificate of incorporation and amended and restated bylaws, all applicable company policies and all applicable laws, rules and regulations, including those promulgated by the SEC. Our corporate governance and nominating committee will evaluate such recommendations in accordance with its charter, our bylaws and corporate governance guidelines and the director nominee criteria described above.
A stockholder that wants to recommend a candidate to our board of directors should direct the recommendation in writing by letter to our corporate secretary at Arcellx, Inc., 800 Bridge Parkway, Redwood City, CA 94065, Attention: Corporate Secretary. Such recommendation must include the candidates name, home and business contact information, detailed biographical data, relevant qualifications, a signed letter from the candidate confirming willingness to serve, information regarding any relationships between the candidate and us and evidence of the recommending stockholders ownership of our capital stock. Such recommendation must also include a statement from the recommending stockholder in support of the candidate. Stockholder recommendations must be received by December31st of the year prior to the year in which the recommended candidate(s) will be considered for nomination. Our corporate governance and nominating committee has discretion to decide which individuals to recommend for nomination as directors.
Under our amended and restated bylaws, stockholders may also directly nominate persons for our board of directors. Any nomination must comply with the requirements set forth in our amended and restated bylaws and the rules and regulations of the SEC and should be sent in writing to our corporate secretary at the address above. To be timely for our 2025 annual meeting of stockholders, nominations must be received by our corporate secretary observing the deadlines discussed below under Other MattersStockholder Proposals or Director Nominations for 2025 Annual Meeting .
Communications with the Board of Directors
Stockholders and other interested parties wishing to communicate directly with our non-management directors, may do so by writing and sending the correspondence to our Chief Executive Officer, Chief Financial Officer or General Counsel by mail to our principal executive offices at Arcellx, Inc., 800 Bridge Parkway, Redwood City, CA 94065. Our Chief Executive Officer, Chief Financial Officer or General Counsel, in consultation with appropriate directors as necessary, will review all incoming communications and screen for communications that (1)are solicitations for products and services, (2)relate to matters of a personal nature not relevant for our stockholders to act on or for our board to consider and (3)matters that are of
-14-
a type that are improper or irrelevant to the functioning of our board or our business, for example, mass mailings, job inquiries and business solicitations. If appropriate, our Chief Executive Officer, Chief Financial Officer or General Counsel will route such communications to the appropriate director(s) or, if none is specified, then to the chairperson of the board or the lead independent director (if one is appointed). These policies and procedures do not apply to communications to non-management directors from our officers or directors who are stockholders or stockholder proposals submitted pursuant to Rule14a-8 under the Exchange Act.
Policy Prohibiting Hedging or Pledging of Securities
Under our insider trading policy, our employees, including our executive officers, and the members of our board of directors are prohibited from, directly or indirectly, among other things, (1)engaging in short sales, (2)trading in publicly-traded options, such as puts and calls, and other derivative securities with respect to our securities (other than stock options, restricted stock units and other compensatory awards issued to such individuals by us), (3)purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engaging in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of equity securities granted to them by us as part of their compensation or held, directly or indirectly, by them, (4)pledging any of our securities as collateral for any loans and (5)holding our securities in a margin account.
Clawback Policy
The Arcellx, Inc. Clawback Policy is our comprehensive policy on recoupment of compensation. This policy covers all individuals who are or were ever designated as an officer by the board of directors in accordance with Exchange Act Rule 16a-1(f). Under this policy, in the event of a financial restatement (whether or not this involves misconduct on the part of the covered individual) or a recalculation of a financial metric affecting an award, we have the right to recover from any covered individual annual incentive payments and gains realized from vested long-term incentive awards. The full text of our clawback policy may be obtained by accessing our filings on the SECs website at www.sec.gov .
Corporate Governance Guidelines and Code of Business Conduct and Ethics
Our board of directors has adopted corporate governance guidelines. These guidelines address, among other items, the qualifications and responsibilities of our directors and director candidates, the structure and composition of our board of directors and corporate governance policies and standards applicable to us in general. In addition, our board of directors has adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including our chief executive officer, chief financial officer and other executive and senior financial officers. The full text of our corporate governance guidelines and code of business conduct and ethics are available on our website at www.arcellx.com. We will post amendments to our code of business conduct and ethics or any waivers of our code of business conduct and ethics for directors and executive officers on the same website.
Non-Employee Director Compensation Policy
Our board of directors has adopted a compensation policy for our non-employee directors. The non-employee director compensation policy was developed with input from our independent compensation consultant regarding practices and compensation levels at comparable companies. It is designed to attract, retain, and reward non-employee directors.
Under the compensation policy, each non-employee director receives the cash and equity compensation for board services described below. We also reimburse our non-employee directors for reasonable, customary, and documented travel expenses to board of directors or committee meetings.
The compensation policy includes a maximum annual limit of $750,000 of cash retainers or fees and equity awards that may be paid, issued, or granted to a non-employee director in any fiscal year, increased to $1,000,000 in the first year an individual becomes a non-employee director. For purposes of this limitation, the value of equity awards is based on the grant date fair value (determined in accordance with GAAP). Any cash compensation paid or equity awards granted to a person for their services as an employee, or for their services as a consultant (other than as a non-employee director), will not count forpurposes of the limitation. The maximum limit does not reflect the intended size of any potential compensation or equity awards to our non-employee directors.
-15-
Cash compensation
Non-employee directors are entitled to receive the following cash compensation for their services under the outside director compensation policy:
| |
$40,000 per year for service as a board member; |
| |
$20,000 per year for service as a lead independent director; |
| |
$15,000 per year for service as chair of the audit committee; |
| |
$7,500 per year for service as a member of the audit committee; |
| |
$10,000 per year for service as chair of the compensation committee; |
| |
$5,000 per year for service as a member of the compensation committee; |
| |
$8,000 per year for service as chair of the corporate governance and nominating committee; and |
| |
$4,000 per year for service as a member of the corporate governance and nominating committee. |
Each non-employee director who serves as the chair of a committee will receive only the additional annual cash fee as the chair of the committee, and not the annual fee as a member of the committee, provided that each non-employee director who serves as the lead independent director will receive the annual fee for service as a board member and an additional annual fee as the lead independent director. All cash payments to non-employee directors are paid quarterly in arrears on a pro-rated basis.
Equity compensation
Initial Award : Each person who first becomes a non-employee director after the date of the effective date of the policy will receive, on the first trading date on or after the date on which the person first becomes a non-employee director, an initial award of a stock option (the Initial Award) covering a number of shares of our common stock having a grant date fair value (determined in accordance with GAAP) equal to $600,000; provided that any resulting fraction will be rounded down to the nearest whole share. Each Initial Award will vest as follows: 1/3rd of the shares subject to the Initial Award will be scheduled to vest each year following the grant date on the anniversary of the grant date, in each case subject to the non-employee director continuing to be a non-employee director through the applicable vesting date. If the person was a member of our board of directors and also an employee, becoming a non-employee director due to termination of employment will not entitle them to Initial Awards.
Annual Award : Each non-employee director automatically will receive, on the first trading day immediately following each annual meeting of our stockholders following the effective date of the policy, an annual award of a stock option (each, an Annual Award) covering a number of shares of our common stock having a grant date fair value (determined in accordance with GAAP) of $300,000; provided that the first Annual Award granted to an individual who first becomes a non-employee director following the effective date of the policy will have a grant date fair value equal to the product of (A) $300,000 multiplied by (B)a fraction, (i)the numerator of which is equal to the number of fully completed days between the non-employee directors initial start date and the date of the first annual meeting of our stockholders to occur after such individual first becomes a non-employee director, and (ii)the denominator of which is 365; and provided further that any resulting fraction will be rounded down to the nearest whole share. Each Annual Award will vest as follows: 100% of the shares subject to the Annual Award will be scheduled to vest upon the earlier of the one-year anniversary of the grant date or the next annual meeting of our stockholders that occurs following the grant date, in each case subject to the non-employee director continuing to be a non-employee director through the applicable vesting date.
In the event of a change in control (as defined in our 2022 Plan), each non-employee director will fully vest in their outstanding company equity awards issued under the director compensation policy, including any Initial Award or Annual Award, immediately prior to the consummation of the change in control provided that the non-employee director continues to be a non-employee director through such date.
-16-
Director Compensation for Fiscal 2023
The following table sets forth information regarding the total compensation awarded to, earned by or paid to our non-employee directors for their service on our board of directors, for the fiscal year ended December31, 2023. Directors who are also our employees receive no additional compensation for their service as directors. During 2023, Mr.Elghandour was an employee and executive officer of the company and therefore did not receive compensation as a director. See Executive Compensation for additional information regarding Mr.Elghandours compensation.
|
Name |
FeesPaidor
Earned in Cash ($) |
Stock
Awards($) |
Option
Awards($) (1) |
Non-Equity
Incentive Plan Compensation($) |
Nonqualified
Deferred Compensation Earnings ($) |
All Other
Compensation($) | Total ($) | |||||||||||||||||||||||||||||||||
|
Jill Carroll |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">54,000 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">299,672 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">353,672 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||
|
Ali Behbahani |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">55,500 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">299,672 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">355,172 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||
|
David Lubner |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">60,000 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">299,672 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">359,672 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||
|
Kavita Patel |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">45,000 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">299,672 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">344,672 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||
|
Olivia Ware |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">44,000 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">299,672 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">343,672 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||
|
Derek Yoon |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">47,500 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">299,672 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">347,172 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||
| (1) |
The amounts reported represent the aggregate grant date fair value of options granted to the named executive officers during the respective fiscal years, as computed in accordance with the Financial Accounting Standards Board Accounting Standards Codification Topic 718 (ASC 718). The assumptions used in the calculation of these amounts are included in Note 2 to the Companys audited consolidated financial statements included in our Annual Report on Form 10-K for our fiscal year ended December31, 2023. |
| (2) |
The following table lists all outstanding equity awards held by non-employee directors as of December31, 2023: |
|
Name |
NumberofSharesUnderlying
Outstanding Stock Awards |
NumberofShares
Underlying OutstandingOptions | ||||||||||||||||||||||||||||||||||||||
|
Jill Carroll |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">11,459 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||||||||
|
Ali Behbahani |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">11,459 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||||||||
|
David Lubner |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">183,822 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||||||||
|
Kavita Patel |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">152,028 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||||||||
|
Olivia Ware |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">66,667 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||||||||
|
Derek Yoon |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">11,459 | VALIGN="bottom"> | |||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | |||||||
|
Audit Fees(1) |
VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">1,810,660 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">1,118,000 | VALIGN="bottom"> | ||
|
Audit-Related Fees(2) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||
|
Tax Fees(3) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">41,973 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">30,000 | VALIGN="bottom"> | ||
|
All Other Fees(4) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2,120 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2,000 | VALIGN="bottom"> | ||
|
Total Fees |
VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">1,854,753 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">1,150,000 | VALIGN="bottom"> | ||
| (1) |
Audit Fees consist of fees billed for professional services rendered in connection with the audit of our financial statements, reviews of our quarterly financial statements, registration statement filings and consents, comfort letters and related accounting consultations and services that are normally provided by the independent registered public accountants in connection with statutory and regulatory filings or engagements for those fiscal years. |
| (2) |
We did not incur Audit-Related Fees for our fiscal years ended December31, 2023 and 2022. |
| (3) |
Tax Fees consist of preparation of our annual state and federal tax returns. |
| (4) |
All Other Fees consist of the annual subscription to Ernst and Young LLPs accounting research and disclosure checklist tools. |
In 2023, there were no other professional services provided by Ernst Young LLP, other than those listed above, that would have required our audit committee to consider their compatibility with maintaining the independence of Ernst Young LLP.
Change of Independent Registered Public Accounting Firm
As previously reported, the audit committee recommended that the Board approve the engagement of PricewaterhouseCoopers LLP to serve as the Companys independent registered public accounting firm for the fiscal year ending December31, 2024, subject to PricewaterhouseCoopers LLPs customary client acceptance procedures and the execution of an engagement letter. The board of directors approved the Audit Committees recommendation on March8, 2024.
The audit report of Ernst Young LLP on the Companys consolidated financial statements as of and for the year ended December31, 2023 did not contain an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles.
-21-
During the Companys fiscal year ended December31, 2023, there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with Ernst Young LLP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure and there were no reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions).
During the fiscal year ended December31, 2023, neither the Company nor anyone on the Companys behalf consulted PricewaterhouseCoopers LLP regarding any of the matters referred to in Item 304(a)(2)(i) or (ii)of Regulation S-K.
Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm
Our audit committee has established a policy governing our use of the services of our independent registered public accounting firm. Under this policy, our audit committee is required to pre-approve all services performed by our independent registered public accounting firm in order to ensure that the provision of such services does not impair such accounting firms independence. All services provided by Ernst Young LLP for our fiscal years ended December31, 2023 and 2022 were pre-approved by our audit committee.
The ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December31, 2024 requires the affirmative vote of a majority of the voting power of the shares present in person (including virtually) or represented by proxy at the annual meeting and entitled to vote thereon. Abstentions will have the same effect as a vote AGAINST this proposal.
OUR BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE RATIFICATION OF THE
APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER31, 2024.
-22-
The audit committee is a committee of the board of directors comprised solely of independent directors as required by Nasdaq listing rules and the rules and regulations of the SEC. The audit committee operates under a written charter adopted by the board of directors. This written charter is reviewed annually for changes, as appropriate. With respect to Arcellxs financial reporting process, Arcellxs management is responsible for (1)establishing and maintaining internal controls and (2)preparing Arcellxs consolidated financial statements. Arcellxs independent registered public accounting firm, Ernst Young LLP, is responsible for performing an independent audit of Arcellxs consolidated financial statements. It is the responsibility of the audit committee to oversee these activities. It is not the responsibility of the audit committee to prepare Arcellxs financial statements. These are the fundamental responsibilities of management. In the performance of its oversight function, the audit committee has:
| |
reviewed and discussed the audited consolidated financial statements with management and Ernst Young LLP; |
| |
discussed with Ernst Young LLP the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board, or PCAOB, and the SEC; and |
| |
received the written disclosures and the letter from Ernst Young LLP required by the applicable requirements of the PCAOB regarding the independent accountants communications with the audit committee concerning independence, and has discussed with Ernst Young LLP its independence. |
Based on the review and discussions noted above, the audit committee recommended to the board of directors that the audited consolidated financial statements be included in Arcellxs Annual Report on Form10-K for the fiscal year ended December31, 2023 for filing with the SEC.
Respectfully submitted by the members of the audit committee of the board of directors:
David Lubner (Chair)
Ali Behbahani
Derek Yoon
This audit committee report shall not be deemed to be soliciting material or to be filed with the SEC or subject to Regulation14A promulgated by the SEC or to the liabilities of Section18 of the Exchange Act, and shall not be deemed incorporated by reference into any prior or subsequent filing by Arcellx under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, except to the extent Arcellx specifically requests that the information be treated as soliciting material or specifically incorporates it by reference.
-23-
The following table sets forth certain information about our executive officers as of April1, 2024.
|
STYLE="border-bottom:1.00pt solid #000000">
Name |
Age |
Position |
||
| Rami Elghandour | 45 | President and Chief Executive Officer | ||
| Michelle Gilson | 32 | Chief Financial Officer | ||
| Christopher Heery | 44 | Chief Medical Officer |
Rami Elghandour . See Mr.Elghandours biography above in the section titled Board of Directors and Corporate Governance.
Michelle Gilson . Michelle Gilson has served as our Chief Financial Officer since May 2022. From April 2021 to May 2022, Ms.Gilson served as a Managing Director at Canaccord Genuity Group Inc., a financial services firm. She also served as a biotech equity research analyst at Canaccord Genuity Group Inc. from March 2018 to April 2022. Prior to joining Canaccord Genuity Group Inc., she served as a Senior Associate at Jefferies LLC, an investment banking firm, from September 2017 to March 2018, an Associate at Instinet LLC (Nomura Group), a financial securities service firm from December 2016 to September 2017, an Associate Director at Oppenheimer Co., Inc., an investment bank and financial services company from January 2015 to November 2016, and an Analyst at Goldman Sachs, an investment bank and financial services company, from June 2014 to January 2015, covering healthcare and biotechnology companies. Ms.Gilson holds a B.S. in Business Administration from the University of Southern California.
Christopher Heery . Christopher Heery, M.D. has served as our Chief Medical Officer since April 2021. Previously, Dr.Heery, served as Chief Medical Officer of Precision BioSciences, Inc., a genome editing company, from May 2019 to April 2021, where he oversaw the clinical development of one of the first allogeneic CAR-T cell platforms and provided clinical insight into clinical efforts for gene editing therapeutics. Dr.Heery also served as Chief Medical Officer at Bavarian Nordic A/S, a biotechnology company, from October 2016 to April 2019, where he oversaw clinical development programs for its immune-oncology and infectious disease portfolios. Prior to that, he was a Staff Clinician and then an Associate Research Physician and Head of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI), a U.S. government health agency, from April 2012 to November 2013 and November 2013 to September 2016, respectively, where he was part of a larger effort to create new immunotherapies for the treatment of cancer. He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and also served as an Adjunct Appointment in the Genitourinary Malignancies Branch. Dr.Heery is board certified in Medical Oncology and Internal Medicine. He received a B.A. from Duke University and a M.D. from East Carolina University Brody School of Medicine and completed his internal medicine residency at the University of Illinois at Chicago.
-24-
Our named executive officers, consisting of our principal executive officer and the two most highly compensated executive officers (other than our principal executive officer), as of December31, 2023, were:
| |
Rami Elghandour, our President and Chief Executive Officer; |
| |
Michelle Gilson, our Chief Financial Officer; and |
| |
Christopher Heery, our Chief Medical Officer. |
Summary Compensation Table for Fiscal 2023
The following table sets forth information regarding the compensation reportable for our named executive officers for fiscal 2023 and prior years where applicable, as determined under SEC rules.
|
Name and Principal Position |
Year |
Salary
($) |
Bonus
($) (1) |
Stock
Awards ($) (2) |
Option
Awards ($) (3) |
Non-Equity
Incentive Plan Compensation ($) |
All Other
Compensation ($) (4) |
Total
($) | ||||||||||||||||||||||||||||||||
|
Rami Elghandour |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">600,960 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">330,000 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">18,754,302 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">5,268,334 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">10,710 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">24,964,306 | VALIGN="bottom"> | ||||||||||||||||
|
Chief Executive Officer |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">565,000 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">450,588 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,757,693 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9,337,815 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9,150 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">14,120,145 | VALIGN="bottom"> | ||||||||||||||||
|
Michelle Gilson |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">416,464 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">176,000 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1,427,939 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1,521,951 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">10,332 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,552,686 | VALIGN="bottom"> | ||||||||||||||||
|
Chief Financial Officer |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">256,308 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">243,600 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">582,688 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1,031,721 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">167,831 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2,114,317 | VALIGN="bottom"> | ||||||||||||||||
|
Christopher Heery |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">480,960 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">192,000 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1,537,785 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1,639,028 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">10,440 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,860,213 | VALIGN="bottom"> | ||||||||||||||||
|
Chief Medical Officer |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">430,000 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">249,400 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1,207,161 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,019,271 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9,150 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">4,914,982 | VALIGN="bottom"> | ||||||||||||||||
| (1) |
The amounts reported for 2023 represent discretionary bonuses paid in lump sum in March 2024 based upon the achievement of company goals for the year ended December31, 2023, as determined by our board of directors. The amounts reported for 2022 represent discretionary bonuses paid in lump sum in March 2023 based upon the achievement of company goals for the year ended December31, 2022, as determined by our board of directors. |
| (2) |
The amounts reported represent the grant date fair value of restricted stock unit (RSU) awards granted to the named executive officers during the respective fiscal years as computed in accordance ASC 718. Such grant-date fair value does not take into account any estimated forfeitures related to performance or service vesting conditions. The assumptions used in calculating the grant date fair value of the awards reported in this column are set forth in Note 2 to our audited consolidated financial statements included in our Annual Report on Form 10-K for our fiscal year ended December31, 2023. |
| (3) |
The amounts reported represent the aggregate grant date fair value of options granted to the named executive officers during the respective fiscal years, as computed in accordance with ASC 718. The assumptions used in the calculation of these amounts are included in Note 13 to the Companys audited consolidated financial statements included in our Annual Report on Form 10-K for our fiscal year ended December31, 2023. |
| (4) |
The amounts reported represent matching contributions under our 401(k) plan and group term life insurance. |
We have entered into employment offer letter agreements with certain of our named executive officers and executive officers in connection with their employment with us. These offer letters provide for at will employment.
Rami Elghandour
In connection with our initial public offering, we entered into a confirmatory offer letter agreement with Mr.Elghandour, our Chief Executive Officer. This agreement has no specific term and provides for at-will employment. Mr.Elghandours current annual base salary is $650,000 and he is eligible for an annual target cash incentive payment of up to 60% of his annual base salary.
Mr.Elghandour will also be eligible to receive certain severance benefits upon an involuntary termination pursuant to a Change in Control and Severance Agreement he has entered into with us, as described in more detail below under the section titled Potential Payments upon Termination or Change in Control .
-25-
Rami Elghandour Equity Awards
On February6, 2021, we granted Mr.Elghandour an option to purchase 1,068,005 shares of our common stock at an exercise price of $8.65 per share, subject to the terms and conditions of our 2017 Plan and a stock option agreement thereunder (the Elghandour Initial Option). On June9, 2021, our board of directors amended the exercise price of the Elghandour Initial Option from $8.65 per share to $6.28 per share. The Elghandour Initial Option may be exercised prior to vesting, subject to Mr.Elghandour executing a restricted stock purchase agreement. The Elghandour Initial Option will vest as to 1/36th of the shares subject to the Elghandour Initial Option on each monthly anniversary of January22, 2021, subject to Mr.Elghandour continuing to be a service provider through each vesting date. The Elghandour Initial Option will, to the extent vested, be exercisable through the earlier of February6, 2031 or the 36-month anniversary of the date Mr.Elghandour ceases to be a service provider, subject to the terms of our 2017 Plan. Mr.Elghandour will be permitted to exercise the Elghandour Initial Option through the issuance of a full recourse promissory note and security agreement in a reasonable form provided by us.
On June9, 2021, we granted Mr.Elghandour an option to purchase 837,602 shares of our common stock at an exercise price of $6.28 per share, subject to the terms and conditions of our 2017 Plan and a stock option agreement thereunder (the Elghandour Second Option). The Elghandour Second Option may be exercised prior to vesting, subject to Mr.Elghandour executing a restricted stock purchase agreement. The Elghandour Second Option will vest pursuant to the same vesting schedule as the Elghandour Initial Option. The Elghandour Second Option will, to the extent vested, be exercisable through the earlier of June9, 2031 or the 36-month anniversary of the date Mr.Elghandour ceases to be a service provider, subject to the terms of our 2017 Plan. Mr.Elghandour will be permitted to exercise the Elghandour Second Option through the issuance of a full recourse promissory note and security agreement in a reasonable form provided by us.
On June9, 2021, we granted Mr.Elghandour an award of restricted stock units covering 952,804 shares of our common stock, subject to the terms and conditions of our 2017 Plan and a restricted stock unit award agreement thereunder (the Elghandour Initial RSU Award). On December7, 2021, we amended the Elghandour Initial RSU Award (the Elghandour Amended Initial RSU Award). The Elghandour Amended Initial RSU Award will vest pursuant to a service component and a performance component. The service component will be satisfied if Mr.Elghandour remains a service provider through the date that our board of directors determines that the applicable performance component is satisfied. The performance component will be satisfied upon our achievement of a company value, as defined in the award agreement underlying the Elghandour Amended Initial RSU Award, as follows: upon achievement of a company value that is equal to $2,500,000,000, or the minimum threshold, 1/6th of the shares subject to the Elghandour Amended Initial RSU Award will vest; upon achievement of a company value that is equal to or greater than $5,000,000,000, or the maximum threshold, 100% of the shares subject to the Elghandour Amended Initial RSU Award will vest; and upon achievement of a company value that is between the minimum threshold and the maximum threshold, a portion of the shares subject to the Elghandour Amended Initial RSU Award will vest between 1/6th and 100% based on straight line linear interpolation. Company value will be measured either (i)on a change in control (as defined in our 2017 Plan) based on the aggregate amount of deal consideration paid at the closing of such change in control by an acquirer for our shares of common stock or (ii)on June30 and December31 of each year following the expiration of any lockup period related to our initial public offering, and will be measured based on the sum of our total market capitalization as of the applicable measurement date, based on the average closing trading price of one share of our common stock over the 60 day period ending on the day prior to such measurement date, less the aggregate value of all cash, cash equivalents and marketable securities held by us on the applicable measurement date.
On January3, 2023, we granted Mr.Elghandour an award of restricted stock units covering 495,000 shares of our common stock, subject to the terms and conditions of our 2022 Plan and a restricted stock unit award agreement thereunder (the Elghandour 2023 RSU Award). The Elghandour 2023 RSU Award will vest pursuant to a service component and a performance component. The service component will be satisfied if Mr.Elghandour remains a service provider through the date that our board of directors determines that the applicable performance component is satisfied. The performance component will be satisfied upon our achievement of a company value, as defined in the award agreement underlying the Elghandour 2023 RSU Award, as follows: upon achievement of a company value that is equal to $2,500,000,000, or the minimum threshold, 1/6th of the shares subject to the Elghandour 2023 RSU Award will vest; upon achievement of a company value that is equal to or greater than $5,000,000,000, or the maximum threshold, 100% of the shares subject to the Elghandour 2023 RSU Award will vest; and upon achievement of a company value that is between the minimum threshold and the maximum threshold, a portion of the shares subject to the Elghandour 2023 RSU Award will vest between 1/6th and 100% based on straight line linear interpolation. Company value will be measured either (i)on a change in control (as defined in our 2022 Plan) based on the aggregate amount of deal consideration paid at the closing of such change in control
-26-
by an acquirer for our shares of common stock or (ii)on June30 and December31 of each year, and will be measured based on the sum of our total market capitalization as of the applicable measurement date, based on the average closing trading price of one share of our common stock over the 60 day period ending on the day prior to such measurement date, less the aggregate value of all cash, cash equivalents and marketable securities held by us on the applicable measurement date.
Christopher Heery, M.D.
In connection with our initial public offering, we entered into a confirmatory employment letter with Dr.Heery, our Chief Medical Officer, effective January31, 2022. The confirmatory employment letter has no specific term and provides for at-will employment. Dr.Heerys current annual base salary is $480,000 and his annual target bonus is 45% of his annual base salary.
Dr.Heery will also be eligible to receive certain severance benefits upon an involuntary termination pursuant to a Change in Control and Severance Agreement he has entered into with us, as described in more detail below under the section titled Potential Payments upon Termination or Change in Control .
Michelle Gilson
We have entered into an employment offer letter with Ms.Gilson, our Chief Financial Officer, effective May23, 2022. The employment offer letter has no specific term and provides for at-will employment. Ms.Gilsons current annual base salary is $475,000 and her annual target bonus is 45% of her annual base salary. Pursuant to her offer letter, Ms.Gilson received a relocation bonus in the net amount of $50,000 (meaning after the deduction of applicable employee withholding obligations) (the Relocation Bonus), and monthly travel reimbursements through December31, 2022 not to exceed a net amount of $5,000 per month or $35,000 in the aggregate (meaning after the deduction of applicable employee withholding obligations) (the Travel Reimbursements Ms.Gilson is required to repay to the Company 50% of the Relocation Bonus and Travel Reimbursements if she voluntarily terminates her employment with the Company prior to the second anniversary of her start date.
Ms.Gilson will also be eligible to receive certain severance benefits upon an involuntary termination pursuant to a Change in Control and Severance Agreement she has entered into with us, as described in more detail below under the section titled Potential Payments upon Termination or Change in Control .
Potential Payments upon Termination or Change in Control
Change in Control and Severance Agreements
Our board of directors has approved, our named executive officers and certain other of our executive officers and key employees have entered into change in control and severance agreements.
Pursuant our named executive officers change in control and severance agreements, if, within the period beginning 3 months prior to or ending 24 months following a change in control (as defined in the applicable agreement) (the Change in Control Period), we terminate the employment of the named executive officer without cause (excluding by reason of death or disability) or the named executive officer resigns for good reason (as such terms are defined in the applicable agreement), such named executive officer will be entitled to receive (i)a lump sum payment equal to the sum of 18 months (24 months with respect to Mr.Elghandour) of such named executive officers then current annual base salary and 150% (200% with respect to Mr.Elghandour) of such named executive officers annual target bonus, less applicable withholdings, (ii)payment of premiums to maintain group health insurance continuation benefits pursuant to the Consolidated Omnibus Reconciliation Act of 1985, as amended (COBRA Coverage) for such named executive officer and such named executives respective eligible dependents for up to 18 months (24 months with respect to Mr.Elghandour) , and (iii)vesting acceleration as to 100% of the then-unvested shares subject to each of such named executive officers then outstanding equity awards subject to time-based vesting conditions (and in the case of awards subject to performance-based vesting conditions, such awards will be treated as provided for in the applicable award agreement governing such award).
-27-
If we terminate the employment of the applicable named executive officer without cause (excluding death or disability) outside of the Change in Control Period or, with respect to Mr.Elghandour, he resigns for good reason, such named executive officer will be entitled to receive (i)a lump sum payment equal to 12 months of such named executive officers then current annual base salary (as well as, with respect to Mr.Elghandour, 100% of his annual target bonus), (ii) COBRA Coverage for up to 12 months, (iii)a lump sum payment equal to such named executive officers annual target bonus, prorated by multiplying such amount by a fraction, (x)the numerator of which is the number of days during which the executive was employed with us in the calendar year that the termination occurs, and (y)the denominator of which is 365, and (iv)with respect to Mr.Elghandour, vesting acceleration as to a number of the then-unvested shares subject to his then-outstanding compensatory equity awards subject to time-based vesting conditions that would have vested had he remained our employee over the 24 month period following the date of termination.
All severance payments and benefits under the Change in Control and Severance Agreements are subject to the named executive officers timely execution a waiver and release of claims in our favor that becomes effective and irrevocable, execution within 60 days following a qualifying termination.
In the event any payment to a named executive would be subject to the excise tax imposed by Section4999 of the Internal Revenue Code, as amended (the Code) (as a result of a payment being classified as a parachute payment under Section280G of the Code), the named executive officer will receive such payment as would entitle such executive to receive thegreatest after-tax benefit, even if it means that we pay such executive a lower aggregate payment so as to minimize or eliminate the potential excise tax imposed by Section4999 of the Code.
2022 Equity Incentive Plan
Our 2022 Plan provides that in the event of a merger or change in control, as defined under our 2022 Plan, each outstanding award will be treated as the administrator determines. The administrator will not be required to treat all awards or portions thereof the vested and unvested portions of an award, or all participants similarly.
In the event that a successor corporation or its parent or subsidiary does not continue an outstanding award, then such award will fully vest, all restrictions on such award will lapse, all performance goals or other vesting criteria applicable to such award will be deemed achieved at 100% of target levels, and such award will become fully exercisable, if applicable, for a specified period prior to the transaction, unless specifically provided for otherwise under the applicable award agreement or other written agreement with the participant. The award will then terminate upon the expiration of the specified period of time. If an option or stock appreciation right is not continued, the administrator will notify the participant in writing or electronically that such option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion and the option or stock appreciation right will terminate upon the expiration of such period.
With respect to awards granted to an outside director, in the event of a change in control, all of his or her options and stock appreciation rights, if any, will vest fully and become immediately exercisable, all restrictions on his or her restricted stock and RSUs will lapse, and all performance goals or other vesting requirements for his or her performance awards will be deemed achieved at 100% of target levels, and all other terms and conditions met.
2017 Equity Incentive Plan
Our 2017 Equity Incentive Plan (the 2017 Plan) provides that in the event of our merger with or into another corporation or entity or a change in control (as defined in our 2017 Plan), each outstanding award will be treated as the administrator determines. The administrator will not be obligated to treat all awards, all awards a participant holds or all awards of the same type, similarly.
In the event that the successor corporation does not assume or substitute for an award (or portion thereof), the participant will fully vest in and have the right to exercise all of his or her outstanding options and stock appreciation rights, including shares as to which such awards would not otherwise be vested or exercisable, all restrictions on restricted stock and restricted stock units will lapse, and, with respect to awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met. In addition, if an option or stock appreciation right is not assumed or substituted in the event of a merger or change in control, the administrator will notify the participant in writing or electronically that the option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion, and the option or stock appreciation right will terminate upon the expiration of such period.
-28-
Outstanding Equity Awards at Fiscal 2023 Year-End
The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December31, 2023.
| Option Awards | Stock Awards | |||||||||||||||||||||||||||||||||||||||
|
Name |
Grant
Date |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
Equity
Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) |
Option
Exercise Price($) |
Option
Expiration Date |
Numberof
Shares or Units of StockThat Have Not Vested (#) |
Market
Value of Shares of Units of Stock That Have Not Vested ($) (21) |
Equity
Incentive Plan Awards: Numberof Unearned Shares, Units or other Rights That Have NotVested (#) |
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(22) | ||||||||||||||||||||||||||||||
|
RamiElghandour |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6/9/2021 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">837,602 | VALIGN="bottom">(1) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6.28 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6/9/2031 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | |||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6/9/2021 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1,068,005 | VALIGN="bottom">(2) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6.28 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6/9/2031 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">12/7/2021 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">158,800 | VALIGN="bottom">(3) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">8,813,437 | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2/3/2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">371,296 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">438,806 | VALIGN="bottom">(4) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">15.00 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2/3/2032 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2/7/2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">140,422 | VALIGN="bottom">(5) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7,793,421 | VALIGN="bottom"> | ||||||||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9/28/2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">27,500 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">92,500 | VALIGN="bottom">(6) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">19.97 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9/28/2032 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">56,150 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">188,905 | VALIGN="bottom">(7) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">31.03 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2033 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">159,292 | VALIGN="bottom">(8) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">8,840,706 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">82,500 | VALIGN="bottom">(3) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">4,578,750 | VALIGN="bottom"> | ||||||||||||||
|
Michelle Gilson |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">5/23/2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">40,974 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">62,541 | VALIGN="bottom">(9) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">8.66 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">5/23/2032 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | |||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">5/23/2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">44,857 | VALIGN="bottom">(10) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2,489,563 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9/28/2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7,447 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">25,053 | VALIGN="bottom">(11) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">19.97 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9/28/2032 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">16,224 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">54,572 | VALIGN="bottom">(12) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">31.03 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2033 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">46,018 | VALIGN="bottom">(13) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2,553,999 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
|
ChristopherHeery |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6/9/2021 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">29,069 | VALIGN="bottom">(14) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6.28 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6/9/2031 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | |||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6/9/2021 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">120,623 | VALIGN="bottom">(15) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6.28 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6/9/2031 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2/3/2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">74,260 | VALIGN="bottom">(16) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">140,945 | VALIGN="bottom">(16) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">15.00 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2/3/2032 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2/7/2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">45,111 | VALIGN="bottom">(17) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2,503,661 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9/28/2022 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9,166 | VALIGN="bottom">(18) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">30,834 | VALIGN="bottom">(18) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">19.97 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9/28/2032 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">17,472 | VALIGN="bottom">(19) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">58,770 | VALIGN="bottom">(19) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">31.03 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2033 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1/3/2023 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">49,558 | VALIGN="bottom">(20) | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2,750,469 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | ||||||||||||||
| (1) |
1/36th of the shares subject to this option vest monthly after the vesting commencement date of January22, 2021, subject to Mr.Elghandours continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. See the section above titled Employment ArrangementsRami Elghandour for additional terms regarding Mr.Elghandours stock options. |
| (2) |
1/36th of the shares subject to this option vest monthly after the vesting commencement date of January22, 2021, subject to Mr.Elghandours continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. See the section above titled Employment ArrangementsRami Elghandour for additional terms regarding Mr.Elghandours stock options. |
| (3) |
See the section above titled Employment ArrangementsRami Elghandour for vesting details of Mr.Elghandours RSUs. |
| (4) |
1/48th of the shares subject to this option vest monthly after the vesting commencement date of February3, 2022, subject to Mr.Elghandours continued status as a service provider through each vest date. |
| (5) |
1/3rd of these RSUs vest annually after the vesting commencement date of February7, 2022, subject to Mr.Elghandours continued status as a service provider through each vest date. |
| (6) |
1/48th of the shares subject to this option vest monthly after the vesting commencement date of January1, 2023, subject to Mr.Elghandours continued status as a service provider through each vest date. |
| (7) |
1/48th of the shares subject to this option vest monthly after the vesting commencement date of January1, 2024, subject to Mr.Elghandours continued status as a service provider through each vest date. |
| (8) |
1/3rd of these RSUs vest annually after the vesting commencement date January3, 2023, subject to Mr.Elghandours continued status as a service provider through each vest date. |
-29-
| (9) |
1/4th of the shares subject to this option will vest on the one-year anniversary of the vesting commencement date of May23, 2022, and 1/48th of the shares subject to this option will vest each month thereafter, subject to Ms.Gilsons continued status as a service provider through each vest date. |
| (10) |
1/3rd of these RSUs vest annually after the vesting commencement date of May23, 2022, subject to Ms.Gilsons continued status as a service provider through each vest date. |
| (11) |
1/48th of the shares subject to this option vest monthly after the vesting commencement date of January1, 2023, subject to Ms.Gilsons continued status as a service provider through each vest date. |
| (12) |
1/48th of the shares subject to this option vest monthly after the vesting commencement date of January1, 2023, subject to Ms.Gilsons continued status as a service provider through each vest date. |
| (13) |
1/3rd of these RSUs vest annually after the vesting commencement date January3, 2023, subject to Ms.Gilsons continued status as a service provider through each vest date. |
| (14) |
1/48th of the shares subject to this option vest monthly after the vesting commencement date of June9, 2021, subject to Dr.Heerys continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. |
| (15) |
1/4th of the shares subject to this option vested on the first anniversary of the vesting commencement date of April26, 2021 and 1/48th of the shares vest monthly thereafter, subject to Dr.Heerys continued status as a service provider through each vest date. All of the shares underlying this option are subject to an early exercise provision, pursuant to which the optionee may exercise the option for shares of restricted stock with the same vesting schedule as would have applied to such shares under the option. |
| (16) |
1/48th of the shares subject to this option vest monthly after the vesting commencement date of February3, 2022, subject to Dr.Heerys continued status as a service provider through each vest date. |
| (17) |
1/3rd of these RSUs vest annually after the vesting commencement date of February7, 2022, subject to Dr.Heerys continued status as a service provider through each vest date. |
| (18) |
1/48th of the shares subject to this option vest monthly after the vesting commencement date of January1, 2023, subject to Dr.Heerys continued status as a service provider through each vest date. |
| (19) |
1/48th of the shares subject to this option vest monthly after the vesting commencement date of January1, 2023, subject to Dr.Heerys continued status as a service provider through each vest date. |
| (20) |
1/3rd of these RSUs vest annually after the vesting commencement date of January3, 2024, subject to Dr.Heerys continued status as a service provider through each vest date. |
| (21) |
This column represents the fair market value of the shares of our common stock as of December31, 2023 subject to the applicable award. The market value has been calculated based on an estimated per-share common stock value of $55.50 per share as of December31, 2023. |
| (22) |
This column represents the fair market value of the shares of our common stock as of December31, 2023 subject to the applicable award that would have vested based on the threshold levels of achievement pertaining to such award. The market value has been calculated based on an estimated per-share common stock value of $55.50 per share as of December31, 2023, and assumes that 1/6th of the shares subject to the applicable award would vest. For additional information regarding these awards, see the section above titled Employment ArrangementsRami Elghandour. |
Equity Compensation Plan Information
The following table summarizes our equity compensation plan information as of December31, 2023. Information is included for equity compensation plans approved by our stockholders. We do not have any equity compensation plans not approved by our stockholders.
|
Plan Category |
(a)Numberof
Securitiestobe Issued Upon Exercise of Outstanding Options,Warrants and Rights |
(b)Weighted-Average
Exercise Price of Outstanding Options, Warrants and Rights |
(c)NumberofSecurities
RemainingAvailablefor Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) | |||||||||||||||||||||
|
Equity compensation plans approved by security holders |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7,811,231 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">12.46 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">11,040,642 | VALIGN="bottom"> | |||||||||||||||
|
Equity compensation plans not approved by security holders |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right"> | VALIGN="bottom"> | |||||||||||||||
|
Total |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7,811,231 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">12.46 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">11,040,642 | VALIGN="bottom"> | |||||||||||||||
| |
Any breach of the directors duty of loyalty to us or to our stockholders; |
| |
Acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; |
| |
Unlawful payment of dividends or unlawful stock repurchases or redemptions; and |
| |
Any transaction from which the director derived an improper personal benefit. |
Similarly, our officers who at the time of an act or omission as to which liability is asserted consented to or are deemed to have consented to certain service of process rules under Delaware law will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as officers, except for liability in connection with:
| |
any breach of their duty of loyalty to us or our stockholders; |
| |
any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; |
| |
any transaction from which they derived an improper personal benefit; or |
| |
any action by or in the right of the corporation. |
If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated certificate of incorporation does not eliminate a directors duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of non-monetary relief, remain available under Delaware law. This provision also does not affect a directors responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Under our amended and restated bylaws, we will also be empowered to purchase insurance on behalf of any person whom we are required or permitted to indemnify.
In addition to the indemnification required in our amended and restated certificate of incorporation and amended and restated bylaws, we have entered, and intend to continue to enter, into an indemnification agreement with each member of our board of directors and each of our officers. These agreements provide for the indemnification of our directors and officers for certain expenses and liabilities incurred in connection with any action, suit, proceeding or alternative dispute resolution mechanism or hearing, inquiry or investigation that may lead to the foregoing, to which they are a party, or are threatened to be made a party, by reason of the fact that they are or were a director, officer, employee, agent or fiduciary of our company, or any of our subsidiaries, by reason of any action or inaction by them while serving as an officer, director, agent or fiduciary, or by reason of the fact that they were serving at our request as a director, officer, employee, agent or fiduciary of another entity. In the case of an action or proceeding by or in the right of our company or any of our subsidiaries, no indemnification will be provided for any claim where a court determines that the indemnified party is prohibited from receiving indemnification. We believe that these charter and bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.
The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. Moreover, a stockholders investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to our directors,
-31-
officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer.
Pay versus Performance Disclosure
As required by Section953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item402(v) of Regulation S-K, we are providing the following information about the relationship between compensation actually paid to our Chief Executive Officer (CEO or PEO) and to our other Named Executive Officers (NEOs) and certain financial performance of the Company. Compensation actually paid, as determined under SEC requirements, does not reflect the actual amount of compensation earned by or paid to our executive officers during a covered fiscal year.
Pay versus Performance Table
|
Year 1 |
Summary
Compensation Table (SCT) Total Compensation for PEO |
Compensation
Actually Paid to PEO 2 |
Average SCT
Total Compensation forOtherNEOs |
Average
Compensation ActuallyPaidto OtherNEOs 3 |
Value of
InitialFixed $100 Investment Based On TSR 4 |
Net
Income ($M) 5 | ||||||||||||||||||
|
2023 |
VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">24,964,306 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">92,921,971 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">3,706,449 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">11,478,651 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">330.36 | VALIGN="bottom"> | VALIGN="bottom">($ | VALIGN="bottom" ALIGN="right">70.7 | VALIGN="bottom">) | ||||||
|
2022 |
VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">14,120,145 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">43,478,874 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">3,514,650 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">5,469,499 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">184.40 | VALIGN="bottom"> | VALIGN="bottom">($ | VALIGN="bottom" ALIGN="right">188.7 | VALIGN="bottom">) | ||||||
| 1. |
The CEO and other NEOs for the indicated years were as follows: (i)for 2023, our CEO was Rami Elghandour and our other NEOs were Michelle Gilson and Christopher Heery, and (ii)for 2022, our CEO was Rami Elghandour and our other NEOs were Michelle Gilson and Christopher Heery. |
| 2. |
Amounts reported in this column are based on total compensation reported for our CEO in the Summary Compensation Table for the indicated fiscal years and adjusted as shown in the tables below. Fair value of equity awards was computed in accordance with the Companys methodology used for financial reporting purposes. The assumptions used in calculating the fair value of such awards are set forth in Note 13 to our audited consolidated financial statements included in our Annual Report on Form 10-K for our fiscal year ended December31, 2023. Compensation actually paid does not mean that our CEO was actually paid those amounts in the listed year, but this is a dollar amount derived from the starting point of Summary Compensation Table total compensation under the methodology prescribed under the SECs rules, as shown in the adjustment table below. |
|
Fiscal Year |
Summary
Compensation Table Total |
Adjustment to
Summary Compensation Table Total a |
Compensation
Actually Paid | |||||||||||||||||||||
|
2023 |
VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">24,964,306 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">67,957,665 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">92,921,971 | VALIGN="bottom"> | |||||||||||||||
|
2022 |
VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">14,120,246 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">29,358,628 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">43,478,874 | VALIGN="bottom"> | |||||||||||||||
| a |
See table below for calculation of Adjustment to Summary Compensation Table Total. |
-32-
|
STYLE="border-bottom:1.00pt solid #000000">
Fiscal
|
Deduction of
GrantDateFair Value of Equity Awards in Summary Compensation Table |
Addition of
YearEndFair ValueofEquity Awards Granted During the Covered Fiscal Year That are Outstanding and Unvested at Fiscal Year End |
Addition
(Deduction)of YearoverYear Change in Fair Value of Outstanding and Unvested Equity Awards |
Addition
(Deduction)of Fair Value as of Vesting DateofEquity Awards Granted and Vested in the Covered Fiscal Year |
Addition
(Deduction)of Change inFair Valuebetween theEnd of the Prior Fiscal Year and the VestingDateof Equity Awards Granted in Prior Fiscal Years that Vested in the Covered Fiscal Year |
Adjustment to
Summary Compensation Table Total | ||||||||||||||||||
|
2023 |
VALIGN="bottom">($ | VALIGN="bottom" ALIGN="right">24,022,636 | VALIGN="bottom">) | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">34,340,706 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">49,225,605 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">1,744,730 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">6,669,260 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">67,957,665 | VALIGN="bottom"> | ||||||
|
2022 |
VALIGN="bottom">($ | VALIGN="bottom" ALIGN="right">13,095,508 | VALIGN="bottom">) | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">6,525,410 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">27,143,638 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">2,447,717 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">6,337,370 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">29,358,628 | VALIGN="bottom"> | ||||||
| 3. |
Amounts reported in this column are based on the average of the total compensation reported for our other NEOs in the Summary Compensation Table for the indicated fiscal years and adjusted as shown in the tables below. Fair value of equity awards was computed in accordance with the Companys methodology used for financial reporting purposes. The assumptions used in calculating the fair value of such awards are set forth in Note 13 to our audited consolidated financial statements included in our Annual Report on Form 10-K for our fiscal year ended December31, 2023. Compensation actually paid does not mean that these NEOs were actually paid those amounts in the listed year, but this is a dollar amount derived from the starting point of Summary Compensation Table total compensation under the methodology prescribed under the SECs rules, as shown in the adjustment table below. |
|
STYLE="border-bottom:1.00pt solid #000000">
Fiscal Year |
Average Summary
CompensationTableTotal |
Adjustment to Average
SummaryCompensationTable Total a |
AverageCompensation
Actually Paid | |||||||||||||||||||||
|
2023 |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,706,450 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7,772,201 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">11,478,651 | VALIGN="bottom"> | |||||||||||||||
|
2022 |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,598,565 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">1,870,934 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">5,469,499 | VALIGN="bottom"> | |||||||||||||||
| a |
See table below for calculation of Adjustment to Average Summary Compensation Table Total for Non-CEO NEOs. |
|
STYLE="border-bottom:1.00pt solid #000000">
Fiscal Year |
Deduction of
Grant Date Fair Value of Equity Awards in Summary Compensation Table |
Addition of
Year End Fair Value of Equity Awards Granted During the Covered Fiscal Year That are Outstanding and Unvested at Fiscal Year End |
Addition
(Deduction)of Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards |
Addition
(Deduction)of FairValueasof Vesting Date of Equity Awards Granted and Vested in the Covered Fiscal Year |
Addition
(Deduction)of ChangeinFair Valuebetweenthe End of the Prior Fiscal Year and theVestingDateof Equity Awards Granted in Prior Fiscal Years that Vested in the Covered Fiscal Year |
Adjustment to
Average Summary Compensation Table Total | ||||||||||||||||||
|
2023 |
VALIGN="bottom">($ | VALIGN="bottom" ALIGN="right">3,063,352 | VALIGN="bottom">) | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">2,652,234 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">6,659,140 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">523,427 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">1,000,753 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">7,772,201 | VALIGN="bottom"> | ||||||
|
2022 |
VALIGN="bottom">($ | VALIGN="bottom" ALIGN="right">2,920,421 | VALIGN="bottom">) | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">2,090,391 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">1,877,378 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">393,101 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">430,485 | VALIGN="bottom"> | VALIGN="bottom">$ | VALIGN="bottom" ALIGN="right">1,870,934 | VALIGN="bottom"> | ||||||
| 4. |
Total shareholder return is calculated by assuming that a $100 investment was made at the close of trading on the first full day of trading of our stock (February4, 2022) and reinvesting all dividends until the last day of each reported fiscal year. |
| 5. |
The dollar amounts reported are the Companys net income reflected in the Companys audited financial statements. |
-33-
Description of the Relationship Between Compensation Actually Paid to our Named Executive Officers and Company Performance
The charts below describe the relationship between compensation actually paid (CAP) for the covered fiscal years to our CEO and the average of the compensation actually paid to our other NEOs (as calculated above) and (i)our cumulative total shareholder return and (ii)our net income.
-34-
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth the beneficial ownership of our common stock as of April1, 2024 by:
| |
each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock; |
| |
each of our named executive officers; |
| |
each of our directors; and |
| |
all of our executive officers and directors as a group. |
We have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated, to our knowledge, the persons or entities identified in the table have sole voting power and sole investment power with respect to all shares shown as beneficially owned by them, subject to community property laws where applicable.
We have based our calculation of the percentage of beneficial ownership on 53,290,315 shares of our common stock outstanding as of April1, 2024. We have deemed shares of our common stock subject to stock options that are currently exercisable or exercisable within 60days of April1, 2024, to be outstanding and to be beneficially owned by the person holding the stock option for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.
Unless otherwise indicated, the address for each person or entity listed in the table is c/o Arcellx, Inc., 800 Bridge Parkway, Redwood City, CA 94065.
| Shares Beneficially Owned | ||||||||
|
Name of Beneficial Owner |
Number | Percentage | ||||||
|
Greater than 5% Stockholders : |
||||||||
|
Gilead Sciences, Inc. (1) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6,720,803 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">12.61 | VALIGN="bottom">% | ||
|
Perceptive Advisors LLC (2) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">4,544,809 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">8.53 | VALIGN="bottom">% | ||
|
FMR LLC (3) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">4,099,861 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7.69 | VALIGN="bottom">% | ||
|
Entities affiliated with New Enterprise Associates (4) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,745,262 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">7.03 | VALIGN="bottom">% | ||
|
Paradigm BioCapital Advisors LP (5) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,658,624 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6.87 | VALIGN="bottom">% | ||
|
BlackRock, Inc. (6) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,018,538 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">5.12 | VALIGN="bottom">% | ||
|
Named Executive Officers and Directors : |
||||||||
|
Rami Elghandour, M.B.A. (7) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">2,609,584 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">4.90 | VALIGN="bottom">% | ||
|
Michelle Gilson (8) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">130,106 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">* | VALIGN="bottom"> | ||
|
Christopher Heery, M.D. (9) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">281,973 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">* | VALIGN="bottom"> | ||
|
Ali Behbahani, M.D., M.B.A. |
||||||||
|
Jill Carroll, M.S. |
||||||||
|
David Lubner, M.S., C.P.A. (10) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">173,509 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">* | VALIGN="bottom"> | ||
|
Derek Yoon, M.B.A |
||||||||
|
Kavita Patel, M.D. (11) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">120,056 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">* | VALIGN="bottom"> | ||
|
Olivia Ware, M.B.A. (12) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">9,402 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">* | VALIGN="bottom"> | ||
|
All directors and executive officers as a group (9 persons) (13) |
VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">3,324,630 | VALIGN="bottom"> | VALIGN="bottom"> | VALIGN="bottom" ALIGN="right">6.24 | VALIGN="bottom">% | ||
| * |
Represents less than 1%. |
| (1) |
Consists of 6,720,803 shares of common stock held by Gilead Sciences, Inc. (Gilead). Gilead has the sole power to vote and dispose these shares, and no person or entity is deemed to have any beneficial ownership or reportable pecuniary interest in the shares held by Gilead. The address for Gilead is 333 Lakeside Drive, Foster City, California 94404. |
| (2) |
Consists of 4,544,809 shares of common stock held by Perceptive Life Sciences Master Fund, Ltd. (the Master Fund). Perceptive Advisors LLC serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Joseph Edelman is the managing member of Perceptive Advisors LLC and may be deemed to beneficially own such shares. The address for each of the Master Fund, Perceptive Advisors LLC and Joseph Edelman is 51 Astor Place, 10th Floor New York, NY 10003. |
| (3) |
Consists of 4,099,861 shares of common stock held by FMR LLC. FMR LLC has the sole power to vote and dispose these shares, and no person or entity is deemed to have any beneficial ownership or reportable pecuniary interest in the shares held by FMR LLC. The address for FMR LLC is 245 Summer Street, Boston, Massachusetts 02210. |
-35-
| (4) |
Consists of 3,745,262 shares of common stock held by New Enterprise Associates 15, L.P. (NEA 15 LP). NEA Partners 15, L.P. (NEA Partners 15) is the sole general partner of NEA 15 LP. NEA 15 GP, LLC (NEA 15 GP) is the sole general partner of NEA Partners 15. Forest Baskett, Anthony A. Florence, Jr., Mohamad Makhzoumi, Scott D. Sandell and Peter Sonsini are the managers of NEA 15 GP. The address for these entities is 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. Dr.Behbahani is a General Partner at New Enterprise Associates, Inc. and a member of our board of directors, and has no voting or dispositive power with respect to any of the above referenced shares and disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interest therein. All indirect holders of the above referenced shares disclaim beneficial ownership of all applicable shares except to the extent of their pecuniary interest therein. |
| (5) |
Consists of 3,658,624 shares of common stock held by Paradigm BioCapital Advisors LP (Paradigm). Paradigm has the sole power to vote and dispose these shares, and no person or entity is deemed to have any beneficial ownership or reportable pecuniary interest in the shares held by Paradigm. The address for Paradigm is 767 Third Avenue, 17th Floor, New York, NY 10017. |
| (6) |
Consists of 3,018,538 shares of common stock held by BlackRock, Inc. (BlackRock). BlackRock has the sole power to vote and dispose these shares, and no person or entity is deemed to have any beneficial ownership or reportable pecuniary interest in the shares held by BlackRock. The address for BlackRock is 50 Hudson Yards, New York, NY 10001. |
| (7) |
Consists of (i) 2,517,245 shares of common stock issuable pursuant to options held directly by Mr.Elghandour exercisable within 60 days of April1, 2024 and (ii) 92,339 shares of common stock held directly by Mr.Elghandour. This does not include 1,790,587 restricted stock units to be settled for shares of common stock held directly by Mr.Elghandour. See the section title Executive CompensationEmployment Arrangements with Our Named Executive OfficersRami Elghandour for vesting details of such restricted stock units. |
| (8) |
Consists of (i) 98,193 shares of common stock issuable pursuant to options held directly by Ms. Gilson exercisable within 60 days of April1, 2024, (ii) 22,428 restricted stock units to be settled for shares of common stock which will vest within 60 days of April1, 2024, and (iii) 9,485 shares of common stock held directly by Ms. Gilson. |
| (9) |
Consists of (i) 273,035 shares of common stock issuable pursuant to options held directly by Dr. Heery exercisable within 60 days of April 14. 2023 and (ii) 8,938 shares of common stock held directly by Dr. Heery. |
| (10) |
Consists of (i) 151,850 shares of common stock issuable pursuant to options held directly by Mr.Lubner exercisable within 60 days of April1, 2024 and (ii) 21,659 shares of common stock held directly by Mr.Lubner. |
| (11) |
Consists of 120,056 shares of common stock issuable pursuant to options held directly by Dr.Patel exercisable within 60 days of April1, 2024. |
| (12) |
Consists of 9,402 shares of common stock issuable pursuant to an option held directly by Ms.Ware exercisable within 60 days of April1, 2024. |
| (13) |
Consists of 3,324,630 shares of common stock beneficially owned by our current directors and executive officers, of which (i) 132,421 are shares of common stock, (ii) 3,169,781 are shares of common stock issuable pursuant to options exercisable within 60 days of April1, 2024, and (iii) 22,428 restricted stock units to be settled for shares of common stock which will vest within 60 days of April1, 2024. |
-36-
Other than compensation arrangements, including employment, termination of employment and change in control arrangements, with our directors and executive officers, the following is a description of each transaction since January1, 2022 and each currently proposed transaction in which:
| |
We have been or are to be a participant; |
| |
The amount involved exceeded or exceeds $120,000; and |
| |
Any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. |
Indemnification Agreements
We have entered, and intend to continue to enter, into separate indemnification agreements with each of our directors and executive officers, in addition to the indemnification provided for in our amended and restated certificate of incorporation and bylaws. The indemnification agreements and our amended restated certificate of incorporation and amended and restated bylaws require us to indemnify our directors, executive officers and certain controlling persons to the fullest extent permitted by Delaware law. See the section titled Executive CompensationLimitation of Liability and Indemnification for additional information.
Participation in Our Initial Public Offering
Entities affiliated with SR One Capital Fund I Aggregator, L.P. (affiliated with director Jill Carroll), a holder of more than 5% of our common stock, purchased 1,666,667 shares of our common stock in our initial public offering at a price of $15 per share.
Entities affiliated with New Enterprise Associates 15, L.P. (affiliated with directors Ali Behbahani and Kavita Patel), a holder of more than 5% of our common stock, purchased 1,583,333 shares of our common stock in our initial public offering at a price of $15 per share.
Novo Holdings A/S., then a holder of more than 5% of our common stock, purchased 833,333 shares of our common stock in our initial public offering at a price of $15 per share.
At our request, the underwriters of our initial public offering in February 2022 reserved up to 5% of the shares of common stock that were offered for sale, at the initial public offering price, to our officers, directors, employees, business associates and related persons.
Participation in Our Secondary Public Offering
Entities affiliated with New Enterprise Associates 15, L.P. (affiliated with directors Ali Behbahani and Kavita Patel), a holder of more than 5% of our common stock, purchased 312,500 shares of our common stock in our secondary public offering at a price of $16.00 per share.
Relationship and transactions with Gilead and Kite
We are parties to the following agreements with Kite Pharma, Inc., a Gilead Company (Kite) and Gilead Sciences, Inc. (Gilead), a beneficial holder of more than 5% of our capital stock:
| |
Collaboration and License Agreement entered into on December9, 2022 between us and Kite and as amended in November 2023, pursuant to which we received upfront cash payments of $225million in February 2023 and $85million in November 2023. Arcellx will be eligible to receive up to approximately $3.9billion in clinical, regulatory, and commercial milestone payments, as further described under the section title Licenses and Collaborations of our Annual Report on Form 10-K for our fiscal year ended December31, 2023. |
-37-
| |
Common Stock Purchase Agreement entered into on December8, 2022 between us and Gilead, pursuant to which Gilead purchased 3,478,261 shares for approximately $100million on January30, 2023. |
| |
Common Stock Purchase Agreement entered into on November15, 2023 between us and Gilead, pursuant to which Gilead purchased 3,242,542 shares for approximately $200million on December28, 2023. Following Gileads purchase of such shares and as of April11, 2024, Gilead holds approximately 12.6% of our outstanding common stock. |
| |
Amended and Restated Standstill and Stock Restriction Agreement entered into on November15, 2023 between us and Gilead, which amended and restated in its entirety the Standstill and Stock Restriction Agreement entered into on December8, 2022 between us and Gilead, pursuant to which Gilead agreed to certain transfer and standstill restrictions. In addition, Gilead is entitled to certain registration rights with respect to the shares held by Gilead following termination of the transfer restrictions; following the termination of such transfer restrictions, Gilead can request that we file a registration statement to register the offer and sale of their shares. These demand registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under certain circumstances. If we determine that it would be materially detrimental to us and our stockholders to effect such a demand registration, we have the right to defer such registration, not more than once in any twelve-month period, for a period of up to 60 days. We will pay all expenses relating to any such registration, subject to specified limitations, and Gileads registration rights will terminate upon the date when Gilead can sell all of its registrable securities without restriction pursuant to Rule 144 promulgated under the Securities Act. |
Related Person Transaction Policy
Our audit committee has the primary responsibility for reviewing and approving or disapproving any related person transaction, which means any transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) or any proposed transaction, arrangement or relationship, between us and any related person in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which such related person has, had or will have a direct or indirect material interest, as contemplated by Item 404(a) of Regulation S-K. The charter of our audit committee provides that our audit committee shall review, approve and monitor related person transactions.
Our board of directors has adopted a formal written policy providing that we are not permitted to enter into any related person transaction without the consent of our audit committee, or under certain circumstances the chair of the audit committee. In approving or rejecting any such transaction, our audit committee is to consider the relevant facts and circumstances available and deemed relevant to our audit committee, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related persons interest in the transaction.
-38-
Stockholder Proposals or Director Nominations for 2025 Annual Meeting
If a stockholder would like us to consider including a proposal in our proxy statement for our 2025 annual meeting pursuant to Rule14a-8 of the Exchange Act, then the proposal must be received by our corporate secretary at our principal executive offices on or before December13, 2024. In addition, stockholder proposals must comply with the requirements of Rule14a-8 regarding the inclusion of stockholder proposals in company-sponsored proxy materials. Proposals should be addressed to:
Arcellx, Inc.
Attention: Corporate Secretary
800 Bridge Parkway
Redwood City, CA 94065
Our amended and restated bylaws also establish an advance notice procedure for stockholders who wish to present a proposal or nominate a director at an annual meeting, but do not seek to include the proposal or director nominee in our proxy statement. In order to be properly brought before our 2025 annual meeting, the stockholder must provide timely written notice to our corporate secretary, at our principal executive offices, and any such proposal or nomination must constitute a proper matter for stockholder action. The written notice must contain the information specified in our amended and restated bylaws. To be timely, a stockholders written notice must be received by our corporate secretary at our principal executive offices:
| |
no earlier than 8:00 a.m., local time, on January24, 2025, and |
| |
no later than 5:00 p.m., local time, on February24, 2025. |
In the event that we hold our 2025 annual meeting more than 25days before or after the one-year anniversary of this years annual meeting, then such written notice must be received by our corporate secretary at our principal executive offices:
| |
no earlier than 8:00 a.m., local time, on the 120th day prior to the day of our 2025 annual meeting, and |
| |
no later than 5:00 p.m., local time, on the later of the 90th day prior to the day of the annual meeting or, if the first public announcement of the date of such annual meeting is less than 100 days prior to the date of such annual meeting, on the 10th day following the day on which public announcement of the date of the annual meeting is first made by us. |
If a stockholder who has notified us of his, her or its intention to present a proposal at an annual meeting of stockholders does not appear to present his, her or its proposal at such annual meeting, then we are not required to present the proposal for a vote at such annual meeting.
A copy of our bylaws, as most recently amended and restated in December 2022, may be obtained by accessing our filings on the SECs website at www.sec.gov . You may also contact our corporate secretary at our principal executive offices for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates.
Our financial statements for our fiscal year ended December31, 2023 are included in our annual report, which we will make available to stockholders at the same time as this proxy statement. Our proxy materials and our annual report are posted on our website at www.proxydocs.com/ACLX and are available from the SEC at its website at www.sec.gov . You may also obtain a copy of our annual report, free of charge, by sending a written request to Arcellx, Inc., 800 Bridge Parkway, Redwood City, CA 94065, Attention: Investor Relations.
-39-
Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this proxy statement, and references to our website address in this proxy statement are inactive textual references only.
* * *
The board of directors does not know of any other matters to be presented at the annual meeting. If any additional matters are properly presented at the annual meeting, the persons named in the proxy will have discretion to vote the shares of our common stock they represent in accordance with their own judgment on such matters.
It is important that your shares be represented at the annual meeting, regardless of the number of shares that you hold. You are, therefore, urged to vote as promptly as possible to ensure your vote is recorded.
THE BOARD OF DIRECTORS
Redwood City, CA
April11, 2024
-40-
Your vote P.O. BOX 8016, CARY, NC 27512-9903 matters! Have your ballot ready and please use one of the methods below for easy voting: Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Scan QR for digital voting Arcellx, Inc. Internet: www.proxypush.com/ACLX Cast your vote online Annual Meeting of Stockholders Have your Proxy Card ready Follow the simple instructions to record your vote For Stockholders of record as of April1, 2024 Phone: Friday, May24, 2024 9:00 AM, Eastern Time 1-866-460-4988 Annual Meeting to be held live via the Internetplease visit Use any touch-tone telephone Have your Proxy Card ready www.proxydocs.com/ACLX for more details Follow the simple recorded instructions Mail: Mark, sign and date your Proxy Card Fold and return your Proxy Card in the postage-paid YOUR VOTE IS IMPORTANT! envelope provided PLEASE VOTE BY: 9:00 AM, Eastern Time, May24, 2024. Virtual: You must register to attend the meeting online and/or participate at www.proxydocs.com/ACLX This proxy is being solicited on behalf of the Board of Directors The undersigned hereby appoints Rami Elghandour, Michele Gilson, and Maryam Abdul-Kareem (the Named Proxies), and each or either of them, as the true and lawful attorneys of the undersigned, with full power of substitution and revocation, and authorizes them, and each of them, to vote all the shares of capital stock of Arcellx, Inc. which the undersigned is entitled to vote at said meeting and any adjournment thereof upon the matters specified and upon such other matters as may be properly brought before the meeting or any adjournment thereof, conferring authority upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given. THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED IDENTICAL TO THE BOARD OF DIRECTORS RECOMMENDATION. This proxy, when properly executed, will be voted in the manner directed herein. In their discretion, the Named Proxies are authorized to vote upon such other matters that may properly come before the meeting or any adjournment or postponement thereof. You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and return this card. PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE Copyright 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved
Arcellx, Inc. Annual Meeting of Stockholders Please make your marks like this: THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ALL THE NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSALS 2, 3 AND 4 BOARD OF DIRECTORS PROPOSAL YOUR VOTE RECOMMENDS 1. To elect three ClassII directors to hold office until our 2027 annual meeting of stockholders and until their respective successors are elected and qualified. FOR WITHHOLD 1.01 Jill Carroll FOR 1.02 Kavita Patel FOR 1.03 Olivia Ware FOR FOR AGAINST ABSTAIN 2. To approve, on an advisory basis, the compensation of the named executive officers FOR identified in the 2023 Summary Compensation Table in the Executive Compensation section of the proxy statement (the Say-on-Pay Vote). 1YR 2YR 3YR ABSTAIN 3. To approve, on an advisory basis, the frequency of future Say-on-Pay Votes. 1 YEAR FOR AGAINST ABSTAIN 4. To ratify the appointment of PricewaterhouseCoopers LLP as our independent FOR registered public accounting firm for our fiscal year ending December31, 2024. 5. To transact other business that may properly come before the annual meeting or any adjournments or postponements thereof. You must register to attend the meeting online and/or participate at www.proxydocs.com/ACLX Authorized SignaturesMust be completed for your instructions to be executed. Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/Vote Form. Signature (and Title if applicable) Date Signature (if held jointly) Date
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|